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This prospective multicentre study assesses long-term impact of genetic testing for breast/ovarian cancer predisposition in a clinical
cohort. Areas evaluated include risk management, distress and insurance problems 3 years post-testing. Participants are adults
unaffected with cancer from families with a known BRCA1/2 mutation. One hundred and ninety-three out of 285 (70% response)
participants at nine UK clinical genetics centres completed assessments at 3 years: 80% female; 37% carriers of a BRCA1/2 mutation.
In the 3 years, post-genetic testing carriers reported more risk management activities than non-carriers. Fifty-five per cent of female
carriers opted for risk reducing surgery; 43% oophorectomy; and 34% mastectomy. Eighty-nine per cent had mammograms
compared with 47% non-carriers. Thirty-six per cent non-carriers X50 years did not have a mammogram post-test. Twenty-two per
cent male carriers had colorectal and 44% prostate screening compared with 5 and 19% non-carriers respectively. Seven per cent
carriers and 1% non-carriers developed cancer. Distress levels did not differ in carriers and non-carriers at 3-year follow-up. Forty per
cent of female carriers reported difficulties with life and/or health insurance. Given the return to pre-test levels of concern among
female non-carriers at 3 years and a substantial minority not engaging in recommended screening, there appears to be a need to help
some women understand the meaning of their genetic status.
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A BRCA1 or BRCA2 gene mutation is associated with increased
risk of breast and/or ovarian cancer (Miki et al, 1994; Wooster
et al, 1995). This presents a number of challenges for the medical
community, patients and their families. Female carriers of BRCA1/
2 mutations (hereafter referred to as female carriers) are at
substantially increased risk of developing breast and/or ovarian
cancer (Ford et al, 1998). Male carriers of BRCA1/2 mutations
(hereafter referred to as male carriers) have an increased risk of
prostate (substantial for BRCA2) and bowel cancer (Ford et al,
1994). Male carriers of BRCA2 mutations are at risk of developing
breast cancer (Easton et al, 1997). Genetic testing is becoming
more widely available and evaluation of the long-term psycholo-
gical impact and risk management strategies used are required.
There are few reports on long-term consequences of BRCA1/2
testing beyond 1 year and most research focuses on women. This is
the first paper to report uptake of risk management options,
psychological distress and insurance problems in a large UK
clinical cohort of men and women 3 years following predictive
testing for BRCA1/2 mutations.
Risk management
Individuals at increased cancer risk are usually offered regular
screening for early detection and/or risk reducing surgery. In the
year following genetic testing, female carriers receive more cancer
screening and risk-reducing surgery relative to pre-test levels and
non-carriers (Watson et al, 2004). In our UK cohort, 28% of
carriers had bilateral risk reducing mastectomy (BRRM) and 31%
oophorectomy (BRRO) in the year following predictive testing. In
the USA, women are less likely to have BRRM (0–15%) than BRRO
(13–51%) (Lerman et al, 2000; Scheuer et al, 2002; Botkin et al,
2003; Schwartz et al, 2003) whereas in the Netherlands the BRRM/
BRRO rate is around 50% for both (Meijers-Heijboer et al, 2000;
Lodder et al, 2002).
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and does not include data from men. One study with long-term
follow-up (5 years post-testing) (van Oostrom et al, 2003) found
most carriers (19 out of 23) had BRRM with fewer (12 out of 23)
having BRRO. Other forms of risk management were not
described. Genetic testing may be of limited value if recommended
screening strategies are not maintained over time. Longer term
follow-up will indicate whether individuals are receiving appro-
priate screening and highlight areas for concern.
Female carriers are typically referred to their local screening
service or breast/gynaecological surgeons for management of their
risk. However, in the year following genetic testing some UK health
services have appeared slow to respond (Watson et al, 2004).
Guidelines have since been published for the management of risk
associated with familial breast cancer within the UK National
Health Service (NHS: provides clinical services free to all at the
point of delivery) (McIntosh et al, 2004). There are no UK
guidelines for the management of ovarian cancer risk or risk
management for male carriers, although PSA screening is likely to
be offered. We assess risk management in the 3 years following
BRCA1/2 mutation testing for breast and ovarian cancer risk in
women and prostate and colorectal cancer risk in men.
Psychological distress
Research has focused on psychological distress experienced by
women following predictive BRCA1/2 testing (Lodder et al, 2001a;
Meiser et al, 2002; Schwartz et al, 2002; van Oostrom et al, 2003).
There is evidence of short-term (a few months following the test
result) adverse effects on emotional well-being with female carriers
experiencing an increase in cancer worry (Meiser et al, 2002;
Watson et al, 2004). Women not expecting to be a carrier
(Schwartz et al, 2002) or experiencing high levels of distress before
genetic testing (Lodder et al, 2001a) are most vulnerable to distress
later. The longer term impact is less clear. Distress has been shown
to return to pre-test levels a year after genetic testing in this
clinical UK cohort (Watson et al, 2004). However, in a smaller
Australian cohort distress remained elevated among carriers a year
following testing (Meiser et al, 2002). Non-carriers on the other
hand are consistently reported to experience reduced levels of
cancer worry following testing, which is maintained at 1 year
(Meiser et al, 2002; Watson et al, 2004).
Far less is known about concerns in the longer term. Increases in
generalised anxiety and depression (although not to clinically
significant levels) have been reported up to 5 years post-test result
in a small group of female carriers (N¼23) and non-carriers
(N¼42) although cancer-related concern did not increase over
this period (van Oostrom et al, 2003). Men have rarely been
included in studies assessing the impact of BRCA1/2 genetic
testing (Lodder et al, 2001b). We assess distress in this study to
identify psychological sequelae for women and men following
predictive genetic testing for BRCA1/2.
Insurance
There has been considerable debate about possible reactions of the
insurance industry to genetic testing. Concern has been expressed
about insurance discrimination (Morrison et al, 1999, 2000). There
is currently a voluntary moratorium in the UK, recently extended
to November 2011 (subject to review in 2008), on the use of
predictive genetic test results by insurance companies when
calculating premiums for life insurance policies under d500000,
critical illness and income protection under d300000 per policy
(Morrison, 2005). In the year following BRCA1/2 testing, 20% of
women with a BRCA1/2 mutation reported problems with
insurance (Watson et al, 2004). We assess the level of insurance
problems in the 3 years post-testing to clarify whether this is a
continuing problem.
In summary, this study includes men and women, unaffected by
cancer at the time of genetic testing, attending nine genetic centres
undertaking the majority of BRCA1/BRCA2 testing in clinical
settings across the UK. Risk management, distress and insurance
problems 3 years post-genetic testing are documented along with
patient reported cancer rates and clinical interventions (e.g.,
biopsies, surgical procedures, screening). Three key questions are
addressed. In the 3 years post-testing:
1. How does BRCA1/2 testing impact upon risk management?
2. What levels of psychological distress exist?
3. What level of insurance problems is reported?
MATERIALS AND METHODS
Participants
A total of 285 adults recruited from nine UK centres were followed
up for 3 years after genetic testing. Eligible participants were
unaffected by cancer and from families with a BRCA1/2 mutation
identified in an affected blood relative. Participants had a 50%
(lower if an intervening relative had died) risk of inheriting a
BRCA1/2 mutation.
Procedure
Using a prospective design, participants were recruited from
genetics clinics between 1997 and 2000. Participants completed a
baseline (pre-genetic test) questionnaire and 3-year follow-up
assessment. Trent multicentre research ethics committee and all
local research ethics committees approved the study. Written
consent was obtained at both time points.
Measures
Demographic data were collected at baseline: age, education level,
marital status, number of children and employment status.
BRCA1/2 mutation status was collected from clinic records at the
end of the study. Individuals found to carry a BRCA1/2 mutation
are referred to as ‘carriers’ and those who do not ‘non-carriers’.
Data on cancer rates were collected from participants.
Risk management Women reported risk management undertaken
in the 3 years following their genetic test using a checklist;
mammography, BRRM (removal of healthy breasts to reduce risk),
BRRO (removal of healthy ovaries to reduce risk), ovarian ultrasound
(Ov US), tamoxifen, clinical examination of breasts by a doctor (CBE)
and breast self-examination (BrSE). Frequency of BrSE and breast/
ovarian biopsy rates were recorded. These data were compared with
women’s responses at baseline indicating whether they had already
undergone these procedures. Men reported colorectal, prostate or
other cancer screening following genetic testing.
Mental health and cancer related concerns: General health
questionnaire 28 – GHQ28 (Goldberg and Hillier, 1979): this 28-
item measure assesses psychiatric disorder (cases) in non-
psychiatric populations and has been used with medical patients.
A total score on the GHQ28 (binary scoring) ranges from 0 to 28. A
cutoff score of X5 is recommended by the test authors as being
clinically significant, that is a score X5 indicates psychiatric
disorder. However, Hopwood et al (1998) recommend X10
(binary scoring) as the cutoff for women with familial cancer risk
to reduce overestimation of cases and this was used in the present
study. Symptoms were assessed in male and female participants.
Cancer worry scale-revised – CWS-R (Lerman et al, 1993; Watson
et al, 1999; Foster et al, 2002): this 6-item scale assesses degree of
worry about developing cancer over the previous 7 days. A total
score on the CWS-R ranges from 6 to 24. A high score indicates
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available. The follow-up data yielded an alpha coefficient of 0.87
(Watson et al, 2004). Cancer worry was assessed in male and
female participants.
Insurance difficulties: Women indicated problems with life,
health or disability insurance post-genetic test and were invited to
specify the nature of these problems. They were not asked if they
had declared the test result to their insurer.
Statistical method
The association between categorical variables was examined using
Fisher’s exact test or w
2 with Yates correction where appropriate.
For ordered categorical variables Mann–Whitney (MW) test for
trend was used. Age was analysed as a continuous variable and
participants were divided into three age groups (o35; 35–49;
450) to reflect variations that might occur in risk management
especially in relation to mammography. Women under 35 years
are unlikely to receive a mammogram and women over 50 years of
age receive regular mammograms as part of the UK National
Screening Programme. Where the o35 and 35–49 year age groups
have similar reports compared to the X50s, the two younger
groups are reported as one (o50).
Scores from GHQ28 and CWS-R were treated as continuous
variables. Normality was tested using the Kolmorgorov–Smirnov
statistic and parametric or non-parametric statistics used as
appropriate. Scores are summarised using mean (m) and standard
deviation (s.d.) or median and range. Groups were compared using
analysis of variance or Kruskal–Wallis (KW) test. Matched data
were used to compare individuals that completed both baseline
and 3-year follow-up questionnaires. Associations between scores
are summarised by Pearson or Spearman correlation coefficients.
Changes in frequency of BrSE post-testing were explored
separately for carriers and non-carriers by w
2 and KW tests.
Predictors of cancer worry were investigated by MW.
RESULTS
Two hundred and eighty-five individuals recruited at baseline
received a genetic test result: 100 (35%) carriers and 185 (65%)
non-carriers. At 3-year follow-up 277 questionnaires were sent out.
Eight individuals were not sent a follow-up questionnaire: two
participants had moved house, one man had died of cancer
(carrier), three participants were persistent non-responders during
one year follow-up and two had previously withdrawn from the
study. Twelve individuals (4%) actively declined participation by
returning blank questionnaires (as requested). One hundred and
ninety-three (70%) participants returned follow-up questionnaires.
A similar proportion of carriers and male participants responded
at baseline and follow-up. More responders were married than
non-responders (P¼0.02; w
2). There were no other significant
differences.
Socio-demographic characteristics of the participants are
presented in Table 1. Sixty per cent of women and 54% of men
are non-carriers. Of the 71 carriers, 48 (68%) had BRCA1, 22 (31%)
BRCA2 and 1 (1%) both BRCA1 and BRCA2 mutations. Of carriers,
48 women and 10 men were o50; five women and eight men X50.
Eighty-four per cent described themselves as Caucasian. Most men
(74%) and women (66%) were employed. Most men (90%) and
women (86%) were married or cohabiting. Forty-nine per cent of
men and 36% of women reported receiving higher education. Five
(7%) carriers and one (1%) non-carrier reported a cancer
diagnosis since genetic testing: two ovarian and one breast cancer
(carriers), two prostate (one carrier; one elderly non-carrier) and
one skin cancer (carrier).
Participants at each centre were compared on demographic
variables. Three centres accounted for 83% of participants. There
were no differences across the three larger centres. Participants
(n¼33) from the six smaller centres were younger (P¼0.04; KW).
How does BRCA1/2 genetic testing impact upon risk
management in the long term?
Female participants Table 2 illustrates risk management options
undertaken at baseline and those undertaken in the 3 years post-
testing according to carrier status and age. There were no
differences in risk management options between carriers and
non-carriers at baseline. This was not the case 3 years later.
Mammography rates were significantly higher (Po0.001; w
2)i n
carriers (89%) compared to non-carriers (46%). Thirty-six per cent
of non-carriers o50 years and 65% of non-carriers X50 years had
a mammogram post-genetic test. The majority of carriers and non-
carriers reported performing BrSE but carriers were more likely to
report increased frequency of BrSE than non-carriers (P¼0.04;
MWtrend).
One non-carrier had BRRM pre-test (not BRRO), four carriers
and 10 non-carriers (9%) had BRRO pre-test. Three per cent
(N¼3) non-carriers had their ovaries removed as part of a
hysterectomy following testing. Fifty-four per cent (21 out of 39) of
carriers with children had BRRO compared to none (0 out of 10)
without (Po0.0001; w
2). Age was not associated with BRRO in
carriers (P¼0.3, MWtrend). Of the carriers opting for BRRM all
were o50 and 11 were o40 at baseline (1 was o30). Ten carriers
had both BRRM and BRRO post-genetic test. Overall, 27 out of 41
(66%) carriers with children had risk reducing surgery compared
to 1 out of 10 without children (P¼0.01; Fisher). Significantly
more carriers had Ov US (Po0.001; w
2) and biopsies (P¼0.05; w
2)
compared to non-carriers. Risk management options undertaken
by BRCA1 and BRCA2 carriers did not differ significantly; 17 out
of 35 (49%) BRCA1 carriers had BRRO by 3 years compared to
four out of 14 (29%) BRCA2 carriers (P¼0.3; Fisher).
BRRM rates for carriers varied from centre to centre, 8–55%.
One centre had a significantly higher rate of BRRM than others
(P¼0.02; Fisher). Baseline cancer worry was not a significant
predictor of risk reducing surgery by 3 years (P¼0.4; KW) and
risk reducing surgery did not reduce cancer worry (P¼0.8; KW) in
carriers by 3-year follow-up. However, numbers are small and this
effect should be interpreted with caution as it is likely to be
underpowered. There was no evidence that cancer worry at
baseline influenced uptake of other risk management options.
Since almost all women reported practicing BrSE, a relationship
with cancer worry can not be tested.
Table 1 Socio-demographic characteristics of the participants
Female Male Total
Participants 154 39 193
Genetic status
Carriers 53 18 71
Non-carriers 101 21 122
Age (years)
a
Median (Range) 42 (23–72) 52 (28–86) 43 (23–86)
o35 33 5 38
35–49 81 12 93
X50 39 22 51
N with offspring
a (daughters)
No. of offspring 21 3 24
1 or more 132 (104) 36 (29) 168 (133)
Unknown 1 0 1
Figures shown are N-values unless indicated otherwise.
aAt baseline.
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Four out of 18 (22%) male carriers had screening for colorectal and
eight out of 18 (44%) for prostate cancer post-genetic test. This
compares to one out of 21 (5%) non-carriers screened for
colorectal and four out of 21 (19%) for prostate cancer. One
additional non-carrier underwent a non-specified biopsy. Of the
carriers, the median age of the men who had prostate screening
was 54 years compared to 37 years for those not screened. Three
out of eight (38%) carriers X50 years had not received screening
post-genetic testing. There was no relationship between cancer
worry at 3 years and self-reported risk management; however,
these numbers are too small to give an adequately powered
analysis.
What levels of psychological distress exist in the long
term?
At 3 years more women than men were identified as cases using
the GHQ28: 18% (nine out of 51) female carriers and 17% (16 out
of 95) non-carriers compared to 11% (two out of 18) of male
carriers and 10% (two out of 21) non-carriers. There were no
significant changes in caseness over time. There was no difference
at baseline (men: P¼0.4; women: P¼1.0; KW) or 3 years (men:
P¼0.8; women P¼0.7; KW) in general mental health between
carriers and non-carriers. However, female carriers did report
higher generalised distress scores at 3 years than at baseline
(P¼0.03) (Table 3).
There was no difference in cancer worry at baseline (women:
P¼0.6; KW) or 3 years (men: P¼0.9; women: P¼0.2; KW) when
comparing carriers and non-carriers. At baseline younger women
(o50 years) were more worried about developing cancer than
older women (Po0.001; KW). There was no such difference at 3
years between older and younger women (carriers: P¼0.5; non-
carriers: P¼1.0; KW) or men (carriers: P¼0.8; non-carriers:
P¼0.7; KW). Female carriers were less worried at 3 years than
they reported at baseline (P¼0.03).
What level of insurance problems is reported?
Overall, 21 (40%) carriers reported insurance problems; three had
not applied for insurance and two did not answer the question
(10% in total). In total, 10 (19%) carriers and four (4%) non-
carriers reported difficulties obtaining life insurance (P¼0.006;
Fisher). Six (11%) carriers and 2 (2%) non-carriers had difficulties
obtaining health insurance. One (2%) carrier reported problems
with disability insurance. Six (11%) carriers and one (1%) non-
carrier reported an increased premium (P¼0.008; Fisher). The
non-carrier’s premium was reduced after the test result. Although
invited to do so few women provided details of problems
experienced.
DISCUSSION
The study participants represent a significant proportion of
patients undergoing predictive genetic testing between 1997 and
2000. This is the first report of data three years following genetic
testing for BRCA1/2 in a clinical cohort in the UK. These data
indicate areas where there may be a need for intervention to
inform and reassure people tested in the longer term. While
carriers engaged in more screening and surgical risk management
there are some potential areas of concern.
Over a third of non-carriers X50 years had not had a
mammogram in the 3 years following their test despite the UK
national breast screening guidelines. We are currently investigat-
ing whether this represents a failure to offer mammography or lack
of attendance in this group of non-carriers thinking they are now
exempt from breast cancer risk. While the uptake of mammo-
graphy in the National Breast Screening Programme is around 75%
(Department of Health, 2004), some women in this study may be
deriving false reassurance from their non-carrier result. Botkin
et al (2003) did not find evidence that non-carriers were falsely
reassured 2 years post-test result in their study.
Table 2 Risk management options given as percentages undertaken by
women at baseline and in the 3 years post-testing according to carrier
status and age
3 year follow-up
Baseline
N¼154
Age group N¼227 Carrier (n¼53) Non-carrier (n¼101)
Mammography
o35 29 81 22
35–49 46 91 44
450 61 100 65
Total 45 89 46
BRRM*
o35 2 38 0
35–49 2 38 0
X50 0 0 0
Total 1 34 0
BRRO+
o35 2 25 0
35–49 10 54 3
450 30 40 7
Total 13 43 3
Breast biopsy*
o35 Not asked 19 9
35–49 19 2
X50 20 6
Total 19 5
Ovarian biopsy+
o35 Not asked 13 0
35–49 4 0
450 0 4
Total 6 1
Ovarian US+
o35 8 81 5
35–49 32 75 16
X50 26 60 25
Total 43 75 17
CBE
o35 35 88 39
35–49 48 81 51
X50 48 100 38
Total 45 85 44
Tamoxifen
o35 0 0 0
35–49 2 6 0
X50 10 20 6
Total 3 6 2
BrSE
o35 85 81 100
35–49 91 97 98
X50 83 100 88
Total 88 91 95
Figures exclude patients who have had BRRM (*) or BRRO (+) as appropriate.
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mammogram post-genetic test. However, the National Breast
Screening Programme does not screen population risk women
until 50 years. While some of these women will have turned 50 in
the 3 years since testing, some may be reluctant to relinquish
screening that was in place before testing. Some women may
continue screening due to other suspected mutations in the family;
however, there appears to be some inappropriate screening within
the non-carrier group.
Female carriers reported higher generalised distress 3 years
following testing than they did at baseline. This was also found by
van Oostrom et al (2003) in their small cohort of female carriers
and non-carriers who reported higher levels of generalised anxiety
and distress 1–5 years following the test result (although not
clinically significant). The increase in generalised distress in the
carrier group suggests that some women may benefit from
additional information or support in the longer term although
this may not be related to concern about developing cancer.
Female non-carriers did not report significantly different levels
of cancer worry compared to baseline. However, in the year
following predictive testing, female non-carriers reported a
substantial reduction in cancer worry, which is not maintained
in the long term (Watson et al, 2004). Mean scores give a general
picture and the range of scores 3 years following genetic testing
indicate that some non-carriers have higher scores which is of
potential concern. Further investigation of both carriers and non-
carriers is warranted to clarify the particular support needs that
may not currently be met in the longer term.
Our findings demonstrate that carriers are more likely than non-
carriers to engage in risk management strategies post-genetic test
where no differences existed at baseline.
Overall, most female carriers (55%) opted for risk reducing
surgery following their genetic test. Our data indicate that most
women who opted for BRRM did so in the year following BRCA1/2
testing while some women waited longer for BRRO. The number of
carriers having BRRO (43%) in the 3 years post-genetic testing was
higher than 1 year post-testing in the same cohort (Watson et al,
2004). This figure is comparable to rates 1 year post-test reported
in the USA (Lerman et al, 2000; Scheuer et al, 2002; Botkin et al,
2003; Schwartz et al, 2003) and slightly lower than reports from the
Netherlands 1 (Meijers-Heijboer et al, 2000; Lodder et al, 2002)
and 5 years following testing (van Oostrom et al, 2003). For BRRM
(34%) the rate is similar to the rate reported at 1 year in this cohort
(Watson et al, 2004). The BRRM rate is higher than in the USA
(Lerman et al, 2000; Scheuer et al, 2002; Botkin et al, 2003;
Schwartz et al, 2003) and lower than in the Netherlands at 1–2
years (Meijers-Heijboer et al, 2000; Lodder et al, 2002) and 5 years
post-testing (van Oostrom et al, 2003).
UK guidelines regarding risk management for women with
familial breast cancer have recently been published (McIntosh
et al, 2004). These National Institute for Clinical Excellence (NICE)
guidelines indicate that BRRM and/or BRRO are appropriate for
BRCA1/2 carriers and should be managed by a multidisciplinary
team. There are no guidelines for the management of women at risk
of ovarian cancer, although research in this area is underway
(UKFOCSS: UK Familial Ovarian Cancer Screening Study). Female
carriers of a BRCA1/2 mutation may be offered regular trans-vaginal
ultrasound and, where appropriate, CA125 testing. There are
considerable doubts regarding the effectiveness of this screening
(Stirling et al,2 0 0 5 ) ,w h i c hm a ye x p l a i nt h eh i g hr a t eo fB R R O .T h i s
screening is not available in the UK outside research trials.
Men did not report significantly different levels of general
distress at baseline or 3-year follow-up, which suggests that testing
for BRCA1/2 genetic mutations does not adversely affect men’s
mental health. This study provides a snapshot of screening
undergone by men following BRCA1/2 testing. Although a
relatively small group, there were significant differences between
carriers and non-carriers in levels of colorectal and prostate
screening. There are no guidelines for the risk management of men
with BRCA1/2 mutations although research is underway (IMPACT:
targeted screening for prostate cancer). Since the study com-
menced bowel cancer risks have become less clear, especially for
BRCA1. Colorectal screening in gene carriers is not generally
recommended unless there is also a significant family history of
colorectal cancer. From April 2006 a national screening pro-
gramme for colorectal cancer was implemented across the UK
(Department of Health, 2006).
Rates of risk reducing surgery varied by clinical genetics centre
and suggest differences in clinical practice impact on risk
management options. Research in larger populations having risk
reducing surgery is warranted. It would be important, now that
guidelines for risk management are in place, to collect further data
on standardisation between centres and equity of access to risk
management services within the NHS.
Table 3 General mental health and cancer specific worry
Baseline 3-year follow-up
Carriers Non-carriers Carriers Non-carriers P*
GHQ females
Mean (s.d) 2.7 (4.6) 2.6 (3.8) 4.5 (6.3)
a 3.7 (5.3) 0.3
Median (range) 0 (0–20) 1 (0–15) 1 (0–27) 1 (0–24)
GHQ males
Mean (s.d) 0.8 (2.6) 1.9 (3.5) 1.6 (3.6) 2.5 (5.1) 0.8
Median (range) 0 (0–11) 0 (0–12) 0 (0–12) 0 (0–17)
GHQ case (X10)
n female 6 (12%) 8 (8%) 9 (18%) 16 (17%) 1.0
n male 1 (6%) 2 (10%) 2 (11%) 2 (10%)
CWS-R females
Mean (s.d) 11.7 (3.1) 11.5 (3.4) 10.4(3.6)
a 9.3 (2.1) 0.2
Median (range) 11 (6–21) 11 (6–22) 10 (6–21) 9 (6–15)
CWS-R males
Mean (s.d) Not measured 8.2 (2.0) 8.1 (2.0)
Median (range) 8 (6–13) 8 (6–11)
GHQ with binary scoring and X10 cutoff to indicate cases. *Comparison of the change from baseline of carriers vs non-carriers.
aSignificant change from baseline P¼0.03.
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difficulties with insurance post-genetic test. In the year following
predictive testing 20% of female carriers reported problems with
insurance (Watson et al, 2004). This indicates that problems with
insurance persist in the long term. We set out to assess the level of
problems experienced around insurance. The high rate of
problems warrants further investigation as precise details of
difficulties experienced were not provided by the women in this
study. Further work is needed to explore the precise nature of
problems experienced. This is a sensitive area and an in-depth
qualitative approach is likely to be appropriate in future research.
In summary, many female carriers opt for risk reducing surgery
post-genetic test and engage in screening, although this varies
across genetics centres. A substantial number of non-carriers X50
did not have a mammogram in the 3 years post-genetic test
contrary to National Breast Screening recommendations. Some
non-carriers may be deriving false reassurance from the genetic
test result. If this is confirmed in other cohorts, there may be some
education needed for women who do not have a genetic fault.
In addition, our data suggest that support may be needed for
some female non-carriers in the long term who report concerns
about developing cancer similar to pre-genetic test levels where an
initial reduction in worry was reported. We have limited data
regarding insurance difficulties experienced by women post-
genetic test result but genetic testing does seem to be raising
problems.
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